Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 — Boston, Massachusetts

Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 is a clinical research site located in Boston, Massachusetts, United States 02115.

Crixeo Health Trust Score: 54/100 (POOR). This profile has not yet been claimed by the site owner.

Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 has participated in 1 clinical trials.

Therapeutic areas: Breast Cancer, Hematologic Neoplasms.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 54/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101?

Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 has a Crixeo Trust Score of 54/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 conducted?

Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 has 1 clinical trials on record. Their work covers Breast Cancer, Hematologic Neoplasms.

Is Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 accredited by Crixeo Health?

Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101 has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Dana Farber Cancer Institute StudyCoordinator:CAUY922A2101?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.